Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RECITE: Romiplostim for Chemotherapy-Induced Thrombocytopenia
NCT03362177Phase 3Completed
- Sponsor
- Amgen
- Start
- Sep 2019
- Primary completion
- Jan 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 20
01
Overview
A Phase 3 trial of romiplostim in chemotherapy-induced thrombocytopenia (CIT), sponsored by Amgen. Started Sep 2019; status: completed.
02
Drugs
romiplostim
03
Conditions
chemotherapy-induced thrombocytopenia (CIT)
Beyond the preview
Go deeper on NCT03362177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03362177.